BRET HAYS: Open Payments
NPI 1912268251 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$294 in 17 payments from 13 companies in 2025. Trend: 2023 $269 · 2024 $211 · 2025 $294
Food & beverage: $294
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 3 | $51 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Boston Scientific Corporation | 1 | $19 |
| Novartis Pharmaceuticals Corporation | 1 | $16 |
| ABBVIE INC. | 1 | $16 |
| Ardelyx, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
Products named: GEMTESA, ZENPEP, INSPIRE, WATCHMAN FLX, VYNDAMAX, ELIQUIS, LEQVIO, VRAYLAR.
Industry payments across NE — which companies pay providers there.
